Orphan Drugs
Rare-disease threshold, the orphan-drug market failure & its statutory incentives (US ODA 1983 · EU Reg 141/2000 · India NDCT 2019) — an RGUHS Paper I/IV LAQ
Past RGUHS · 6
RGUHSSep '25
RGUHSMay '18
RGUHSNov '17
RGUHSJun '16
RGUHSMay '09
RGUHSSep '06
Definition & concept
- Definition — An orphan drug is a pharmaceutical that benefits only a small number of patients — i.e. one developed to treat a rare disease ("orphan disease") for which, under normal free-market conditions, industry has little commercial incentive to develop or market a medicine.
- The economic problem captured — A free market is liable to leave untreated both (i) rare diseases (e.g. some cancers) in all countries, and (ii) some common diseases of poor countries (e.g. malaria, schistosomiasis) — both are economically "orphaned."
- Who funds them — Because investor-owned companies generally cannot afford to develop products for rare diseases, funds to invent such drugs often come from taxpayers or philanthropists rather than private capital.
- EU usage — Medicines intended for these small populations are termed "orphan medicinal products" in European regulatory usage.
Continue reading
Orphan Drugs
PharmaNotes Pro · LAQ
Sign in with your Google account. If you're already subscribed, the chapter unlocks immediately — otherwise, pick Monthly or Annual on the next step.